You are here

Home » Content

Diltiazemin Böbrek İşlevleri Üzerine Kısa Dönem Etkileri: Bir Kontrollü Klinik Çalışma

Short Term Effects of Diltiazem on Renal Functions: A Controlled Clinical Study

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2012
DOI: 
DOI 10.5262/tndt.2012.1002.05

Key Words:

Keywords (Original Language):

Author NameFaculty of Author
Abstract (2. Language): 
Obj ectı ve: We aimed to study acute effects of diltiazem on renal functions and its renoprotective effects in patients with chronic kidney disease (CKD). MATER IAL and Methods : Among patients with CKD followed-up in our unit, fifty patients using diltiazem as a part of their treatment(the treatment group) and fifty patients not using diltiazem (the control group) were selected. Besides demographic parameters; blood pressures, creatinine, proteinuria and creatinine clearance levels at the baseline, first week, and third and sixth months were recorded. Results : The groups were matched for the mean creatinine clearance at baseline. The course of mean creatinine clearance were similar in both groups (p=0.29). There was no significant change in serum creatinine or creatinine clearance after initiation of diltiazem in the treatment group. Baseline proteinuria was higher in treatment group (p=0.012). Proteinuria at the sixth month was significantly higher in the control group compared with basal and first week levels (p<0.001 and p=0.007, respectively). But there was no change in the treatment group regarding proteinuria. Serum albumin levels were not statistically significantly different in the groups (p=0.69). Conc lusion : Diltiazem has no acute effect on serum creatinine and creatinine clearance in patients with CKD. It may prevent the probable increase in proteinuria.
Bookmark/Search this post with
Abstract (Original Language): 
Amaç : Çalışmamızda, diltiazemin böbrek işlevleri üzerine akut etkilerini ve kronik böbrek hastalığı (KBH) olan hastalarda böbrek koruyucu etkilerini çalışmayı amaçladık. GEREç ve Yönt emLER : Ünitemizde izlenmekte olan KBH hastalarından, tedavilerinin bir parçası olarak diltiazem kullanan elli hasta (tedavi grubu) ile diltiazem kullanmayan elli hasta (kontrol grubu) çalışma için seçildi. Demografik göstergeler yanında kan basınçları, kreatinin, proteinüri ve kreatinin klirensi değerleri başlangıçta, ilk haftada ve üçüncü ile altıncı aylarda kaydedildi. Bulgular: Başlangıç değerlendirmesinde gruplar kreatinin klirensi açısından tam olarak benzerdi. Ortalama kreatinin klirensinin seyri her iki grupta benzerdi (p=0.29). Tedavi grubunda, diltiazen başlanmasından itibaren serum kreatinin ve kreatinin klirensi değerlerinde anlamlı değişiklik yoktu. Başlangıç proteinüri değerleri tedavi grubunda daha yüksekti (p=0.012). Kontrol grubunda altıncı aydaki proteinüri değerleri, başlangıç ve ilk hafta değerleri ile karşılaştırıldığında anlamlı olarak yüksekti (p<0.001 ve p=0.007). Fakat tedavi grubunda proteinüri açısından değişiklik yoktu. Serum albümin düzeyleri tedavi ve kontrol gruplarında istatistiksel anlamlı olarak farklı değildi (p=0.69). Son uç: Diltiazemin diabetikler de dahil olmak üzere proteinürisi olan hastalarda serum kreatinin ve kreatinin klirensi değerleri üzerine akut etkisi yoktur. Proteinürideki muhtemel artmayı engelleyebilir.
FULL TEXT (PDF): 
PDF icon arastrmx_172977_21_pp_130-135.pdf
  • 2
130-135
  • Turkish

REFERENCES

References: 

1. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, Marcantoni
C, de Jong PE, de Zeeuw D, Shahinfar S, Ruggenenti P, Remuzzi
G, Levey AS, AIPRD Study Group: Angiotensin-converting
enzyme inhibition and progression of renal disease: Proteinuria as
a modifiable risk factor for the progression of non-diabetic renal
disease. Kidney Int 2001; 60: 1131-1140
2. Williams PS, Fass G, Bone JM: Renal pathology and proteinuria
determine progression in untreated mild/moderate chronic renal
failure. Q J Med 1988; 67: 343-354
3. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB,
Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group:
Renoprotective effect of the angiotensin-receptor antagonist
irbesartan in patients with nephropathy due to type 2 diabetes.
N Engl J Med 2001; 345: 851-860
4. Keane WF, Lyle PA: Reduction of end points in NIDDM with the
angiotensin II receptor antagonist losartan study: Recent advances
in management of type 2 diabetes and nephropathy: Lessons from
the RENAAL study. Am J Kidney Dis 2003; 41 (3 Supp 1): 22-25
5. Parving HH, Lehnert H, Brochner-Mortensen, Gomis R, Andersen
S, Arner P: The effect of irbesartan on the development of diabetic
nephropathy in patients with type 2 diabetes. N Engl J Med 2001;
345: 870-878
6. Bakris GL, Weir MR, Secic M, Campbell B, Weis-McNulty A:
Differential effects of calcium antagonist subclasses on markers of
nephropathy progression. Kidney Int 2004; 65: 1991
7. Cockcroft DW, Gault MH: Prediction of creatinine clearance from
serum creatinine. Nephron 1976; 16: 31-41
8. Kloke HJ, Branten AJ, Huysmans FT, Wetzels JF: Antihypertensive
treatment of patients with proteinuric renal diseases: Risks or
benefits of calcium channel blockers? Kidney Int 1998; 53:
1559-1573
9. Gansevoort RT, Sluiter WJ, Hemmelder MH, de Zeeuw D, de Jong
PE: Antiproteinuric effect of blood-pressure-lowering agents: A
meta-analysis of comparative trials. Nephrol Dial Transplant 1995;
10: 1963-1974
10. Ruggenenti P, Perna A, Benini R, Remuzzi G; for the GISEN group:
Effects of dihydropyridine calcium channel blockers, angiotensinconvertizing
enzyme inhibition, and blood pressure control on
chronic, nondiabetic nephropathies. J Am Soc Nephrol 1998; 9:
2096-2101
11. Smith AC, Toto R, Bakris GL: Differential effects of calcium
channel blockers on size selectivity of proteinuria in diabetic
glomerulopathy. Kidney Int 1998; 54 (3): 889-896
12. ter Wee PM, De Micheli AG, Epstein M: Effects of calcium
antagonists on renal hemodynamics and progression of nondiabetic
chronic renal disease. Arch Intern Med 1994; 154 (11): 1185-1202
13. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S: Calcium
channel blockers versus other antihypertensive therapies on
progression of NIDDM associated nephropathy. Kidney Int 1996;
50 (5): 1641-1650
14. Slataper R, Vicknair N, Sadler R, Bakris GL: Comparative effects
of different antihypertensive treatments on progression of diabetic
renal disease. Arch Intern Med 1993; 153 (8): 973-980
15. Anderson S: Renal hemodynamic effects of calcium antagonists in
rats with reduced renal mass. Hypertension 1991; 17 (3): 288-295
16. Carmines PK, Navar LG: Disparate effects of Ca channel blockade
on afferent and efferent arteriolar responses to ANG II. Am J Physiol
1989; 256: F1015-1020

Thank you for copying data from http://www.arastirmax.com